Xiaodong Peng

Xiaodong Peng

Auto-generated profile, based on publicly available information

Xiaodong Peng

Department of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
XLXinmeng Liu
Xinmeng Liu
RLRong Lin
Rong Lin
XPXiaodong Peng
Xiaodong Peng
XWXuesi Wang
Xuesi Wang
YLYukun Li
Yukun Li
NLNian Liu
Nian Liu
Objective: This study aimed to evaluate the feasibility of real-time visualization and mapping of the right phrenic nerve (RPN) by using intracardiac echocardiography (ICE) during atrial fibrillation (AF) ablation.Background: RPN injury is a complication associated with the ablation of AF. Multiple approaches are currently being used to prevent and detect RPN injuries. However, none of these approaches can directly visualize the RPN in real-time during the ablation procedure.Methods and results: The RPN was detected using ICE. The RPN and its adjacent structures were analysed. The relationship between the RPN’s distance from the superior vena cava (SVC) and its pacing capture threshold was quantified. The safety of SVC isolation guided by the ICE-visualized RPN was evaluated. Thirty-eight people were enrolled in this study. The RPN was visualized by ICE in 92% of patients. It ran through the space between the SVC and the mediastinal pleura and had a ‘straw’-like appearance upon ICE imaging. The course of the RPN was close to the SVC (minimum 1.0 ± 0.4 mm) and the right superior pulmonary vein (minimum 14.1 ± 7.3 mm). There was a positive linear correlation between the RPN’s capture threshold and its distance from the SVC (Spearman’s correlation coefficient = 0.728, < 0.001). SVC isolation was guided by the RPN; none of the patients developed an RPN injury.Conclusions: RPN can be visualized by ICE in most patients, thus providing a novel approach for the real-time detection of RPN during AF ablation.

1 October 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
XPXiaodong Peng
Xiaodong Peng
YLYukun Li
Yukun Li
NLNian Liu
Nian Liu
SXShijun Xia
Shijun Xia
XLXin Li
Xin Li
CMChangsheng Ma
Changsheng Ma
BACKGROUND: Currently, there are no reliable methods for predicting and preventing atrial fibrillation (AF) in its early stages. This study aimed to identify plasma proteins associated with AF to discover biomarkers and potential drug targets. METHODS: The UK Biobank Pharma Proteomics Project examined 2923 circulating proteins using the Olink platform, forming the basis of this prospective cohort study. The UK Biobank Pharma Proteomics Project included a randomly selected discovery cohort and the consortium-selected replication cohort. The study’s end point was incident AF, identified using International Classification of Diseases, Tenth Revision codes. The association between plasma proteins and incident AF was evaluated using Cox proportional hazard models in both cohorts. Proteins present in both cohorts underwent Mendelian randomization analysis to delineate causal connections, utilizing cis -protein quantitative trait loci as genetic tools. The predictive efficacy of the identified proteins for AF was assessed using the area under the receiver operating characteristic curve, and their druggability was explored. RESULTS: Data from 38 784 participants were included in this study. Incident AF cases were identified in the discovery cohort (1894; 5.5%) within a median follow-up of 14.5 years and in the replication cohort (451; 10.6%) within a median follow-up of 14.4 years. Twenty-one proteins linked to AF were identified in both cohorts. Specifically, COL4A1 (collagen IV α-1; odds ratio, 1.11 [95% CI, 1.04–1.19]; false discovery rate, 0.016) and RET (proto-oncogene tyrosine-protein kinase receptor Ret; odds ratio, 0.96 [95% CI, 0.94–0.98]; false discovery rate, 0.013) demonstrated a causal link with AF, and RET is druggable. COL4A1 improved the short- and long-term predictive performance of established AF models, as evidenced by significant enhancements in the area under the receiver operating characteristic, integrated discrimination improvement, and net reclassification index, all with P values below 0.05. CONCLUSIONS: COL4A1 and RET are associated with the development of AF. RET is identified as a potential drug target for AF prevention, while COL4A1 serves as a biomarker for AF prediction. Future studies are needed to evaluate the effectiveness of targeting these proteins to reduce AF risk.

4 January 2022 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
XPXiaodong Peng
Xiaodong Peng
LLLinling Li
Linling Li
RLRong Lin
Rong Lin
XWXuesi Wang
Xuesi Wang
XLXinmeng Liu
Xinmeng Liu
NLNian Liu
Nian Liu

13 March 2025 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
XKXiangyi Kong
Xiangyi Kong
MLMingxiao Li
Mingxiao Li
LHLiu He
Liu He
YLYiwei Lai
Yiwei Lai
JWJue Wang
Jue Wang
CMChangsheng Ma
Changsheng Ma

22 September 2023 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
XPXiaodong Peng
Xiaodong Peng
LHLiu He
Liu He
NLNian Liu
Nian Liu
YRYanfei Ruan
Yanfei Ruan
XZXin Zhao
Xin Zhao
CMChangsheng Ma
Changsheng Ma

29 January 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
JLJiaju Li
Jiaju Li
YLYiwei Lai
Yiwei Lai
CJChao Jiang
Chao Jiang
MLMingxiao Li
Mingxiao Li
ZYZejun Yang
Zejun Yang
JDJianzeng Dong
Jianzeng Dong
Aims: Fibroblast growth factor 23 (FGF23) has been implicated in the occurrence of atrial fibrillation (AF), but its prognostic value in AF patients remains unclear. Methods and results: A total of 35 197 AF patients with available follow-up data (3.56, 0.47–8.92 years) from the UK Biobank were included. Clinical association between serum FGF23 and AF-related outcomes including mortality, heart failure (HF), ischaemic stroke, and dementia were analysed using multivariable Cox regression. In those passed quality control for array sequencing, polygenic score for FGF23 (PGSFGF23) was calculated as genetic instrument, and the association between PGSFGF23 and the occurrence of endpoints after first AF diagnosis were further explored. In 886 patients who diagnosed AF at or prior to the enrolment, elevated serum FGF23 levels were significantly associated with an increased risk of all-cause (37% increase per standard deviation) and cardiovascular (40% increase per standard deviation) mortality and HF (43% increase per standard deviation). A total of 35 197 patients were available for genetic array sequencing data. Using polygenic score including seven independent SNPs reaching genome-wide significance threshold, genetic association analysis indicated that increased PGSFGF23 is associated with reduced risk of HF but increased risk of all-cause mortality and ischaemic stroke. Conclusion: Our findings suggest that FGF23 is a potential biomarker for accessing AF-related outcomes. The paradoxical association between genetic FGF23 and serum FGF23 level highlights the need for further investigation to elucidate the underlying mechanisms.